Moteur de recherche d’entreprises européennes
Financement de l’UE (2 892 171 €) : Évaluation d’urgence du sang et du plasma convalescents pour la maladie virale Ebola (MVE) dans les pays touchés d’Afrique de l’Ouest. Hor01/11/2014 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Évaluation d’urgence du sang et du plasma convalescents pour la maladie virale Ebola (MVE) dans les pays touchés d’Afrique de l’Ouest.
The objective of this proposal is to urgently determine the efficacy, safety and feasibility of convalescent whole blood (CWB) and convalescent plasma (CP) therapy, as a treatment for patients with Ebola Viral Disease (EVD) to reduce the case fatality rate in the present EVD epidemic in West Africa. The trial will take place in three consecutive phases; i) initial phase to initiate harmonized standard supportive care (SC), ii) evaluation of CWB iii) evaluation of CP. Supportive care (SC) including intravenous hydration and shock management will be standardised and made available to all patients. Day 14 mortality will be used to determine primary outcome. Survival for patients treated with CWB + SC or CP + SC will be compared to SC alone using a non-randomised open-label design. Based on available figures, a 20% decrease in the case fatality rate will be considered proof of clinical efficacy. Internationally agreed stands of ethics and human rights will be applied for the duration of the trial. Written consent will be requested from patients and/or guardians of patients. Every consideration will be given to the safely of health-care workers involved in the trial, including their consent to be involved and adequate training and psycho-emotional support. Given the study context, community communication will be prioritized. We propose a unique partnership of academics, clinical trial units, non-governmental organizations, international research networks, international and local actors to conduct a clinical trial according to the highest standards attainable in the current context. If found to be effective, this intervention can be scaled-up relatively rapidly as the trial will provide the information required to mobilize local partners, with major public health implications.
| Etablissement Francais du Sang | 385 775 € |
| Institut National de la Sante et de la Recherche Medicale | 47 166 € |
| Institut Pasteur | 242 910 € |
| Instituut Voor Tropische Geneeskunde | 1 803 778 € |
| London School of Hygiene and Tropical Medicine Royal Charter | 60 110 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 49 100 € |
| The University of Liverpool | 85 180 € |
| Universite d'AIX Marseille | 218 151 € |
https://cordis.europa.eu/project/id/666094
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
